RETRATUTIDE INJECTION 150mg
Gs. 0
Skip to product information
RETRATUTIDE INJECTION 150mg
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes[2][3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability[1][4].
- Reconstitute: Add 5.0 mL bacteriostatic water → 30.0 mg/mL concentration for optimal weekly doses.
- Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
- Easy measuring: At 30.0 mg/mL, 1 unit = 0.01 mL ≈ 0,3 mg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Standard / Gradual Titration Approach (5 mL = 30.0 mg/mL)
| Week(s) | Weekly Dose (mcg) (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2,000 mcg (2 mg) | 6,67 UI |
| Weeks 5–8 | 4,000 mcg (4 mg) | 13,33 UI |
| Weeks 9–12 | 8,000 mcg (8 mg) | 26,67 UI |
| Weeks 13+ | 12,000 mcg (12 mg) | 40 UI |
Frequency: Inject once weekly subcutaneously. This schedule follows clinical trial protocols that demonstrated significant weight loss (up to 24% at 48 weeks with 12 mg weekly)[2] while minimizing gastrointestinal adverse events through gradual escalation[1][4].
Reconstitution Steps
- Draw 5.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
